Smallpox Virus

Joint venture completes phase I vaccinia immune globulin trial

Published in TB and Outbreaks Week, August 26th, 2003

Computer Sciences Corporation (CSC) announced that DynPort Vaccine Company LLC (DVC), a joint venture between CSC and Porton International, has completed a second phase I clinical trial to evaluate the safety of vaccinia immune globulin, an antiserum used to counteract adverse reactions to smallpox vaccination.

No serious adverse events were reported.

Phase I testing evaluated the safety of vaccinia immune globulin in 33 healthy volunteers at a clinical research facility in Lenexa, Kansas. Each volunteer received a dose of 100 milligrams of vaccinia immune globulin per kilogram of body weight. There were no serious adverse events among the study...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (2003-08-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry